ANN ARBOR STAGE III GRADE 3 FOLLICULAR LYMPHOMA
Clinical trials for ANN ARBOR STAGE III GRADE 3 FOLLICULAR LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new ANN ARBOR STAGE III GRADE 3 FOLLICULAR LYMPHOMA trials appear
Sign up with your email to follow new studies for ANN ARBOR STAGE III GRADE 3 FOLLICULAR LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug cocktail shows promise for Hard-to-Treat lymphoma
Disease control OngoingThis study is testing a combination of three drugs—ALX148, rituximab, and lenalidomide—in people with B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. The goal is to find the best dose and see if the combination can shrink or control the cancer. About…
Matched conditions: ANN ARBOR STAGE III GRADE 3 FOLLICULAR LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 23, 2026 12:01 UTC
-
New cocktail of three drugs shows promise for lymphoma patients
Disease control OngoingThis early-phase trial is testing a combination of three drugs—rituximab, lenalidomide, and ibrutinib—in people with previously untreated follicular lymphoma. The goal is to find the safest dose and see how well patients tolerate the treatment. About 33 participants with stage II…
Matched conditions: ANN ARBOR STAGE III GRADE 3 FOLLICULAR LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 23, 2026 11:55 UTC
-
New drug cocktail aims to shrink lymphoma without chemo
Disease control OngoingThis phase II trial tests a combination of three drugs—acalabrutinib, lenalidomide, and rituximab—in 60 people with untreated follicular lymphoma that has spread. The goal is to see if this chemo-free mix can make the cancer disappear completely. Participants take the drugs by mo…
Matched conditions: ANN ARBOR STAGE III GRADE 3 FOLLICULAR LYMPHOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 22, 2026 11:55 UTC